AKIVA DIAMOND to Aged, 80 and over
This is a "connection" page, showing publications AKIVA DIAMOND has written about Aged, 80 and over.
Connection Strength
0.064
-
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80?years or older: A retrospective cohort study. Cancer Lett. 2024 Aug 01; 596:217001.
Score: 0.024
-
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. JAMA Oncol. 2021 Dec 01; 7(12):1856-1861.
Score: 0.020
-
Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates. Clin Lymphoma Myeloma Leuk. 2021 11; 21(11):799-804.
Score: 0.020